Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase I Pipeline Programs

First-in-human and early clinical safety studies in Phase I.

Programs 4,713
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 4,713 phase i pharmaceutical pipeline programs from ClinicalTrials.gov. First-in-human and early clinical safety studies in Phase I.

Top sponsors

Pipeline programs

Page 53 of 99

  1. LGD-6972 Solution

    LIGAND PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus (T2DM)

    phase 1 small molecule completed

    1 trial

  2. LGH447

    Novartis Pharmaceuticals

    AML and High Risk MDS

    phase 1 small molecule completed

    1 trial

  3. LGH447

    Novartis Pharmaceuticals

    Relapsed and Refractory Multiple Myeloma

    phase 1 small molecule completed

    1 trial

  4. LIDEXU

    Lacuna Pharma Pty Ltd

    bioavailability trial with healthy participants, therapeutic indication not studied

    phase 1 other active

    1 trial

  5. LISDE-01-25

    Lacuna Pharma Pty Ltd

    ADHD (Attention Deficit Hyperactivity Disorder), BED (Binge Eating Disorder)

    phase 1 other active

    1 trial

  6. LISDE-06-24

    Lacuna Pharma Pty Ltd

    ADHD

    phase 1 other active

    1 trial

  7. LISDE-14-24

    Lacuna Pharma Pty Ltd

    ADHD

    phase 1 other active

    1 trial

  8. LN-144

    Iovance Biotherapeutics B.V.

    Stage IIIB Melanoma

    phase 1 mab terminated

    1 trial

  9. LN-145/LN-144

    Iovance Biotherapeutics B.V.

    Soft Tissue Sarcoma

    phase 1 mab active

    1 trial

  10. LNZ101 (Aceclidine /Brimonidine) ophthalmic solution

    LENZ Therapeutics

    Presbyopia

    phase 1 small molecule completed

    1 trial

  11. LOR-253 HCl

    Aptose Biosciences

    Advanced or Metastatic Solid Tumours

    phase 1 small molecule completed

    1 trial

  12. LOXO-ENC-23001

    Eli Lilly Co.

    Advanced/metastatic solid tumor

    phase 1 other active

    1 trial

  13. LOXO-FRA-24001

    Eli Lilly Co.

    Ovarian cancer, endometrial cancer, cervical cancer, non-small cell lung cancer, triple-negative breast cancer, pancreatic cancer and colorectal cancer.

    phase 1 other active

    1 trial

  14. LOXO-IDH-20001

    Eli Lilly Co.

    Advanced Hematologic Malignancies

    phase 1 other active

    1 trial

  15. LOXO-LNC-24001

    Eli Lilly Co.

    Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors

    phase 1 other active

    1 trial

  16. LOXO-PIK-21001

    Eli Lilly Co.

    Advanced Breast Cancer and Other Solid Tumors

    phase 1 other active

    1 trial

  17. LP0189-2318

    LEO Pharma A/S

    Gout flares

    phase 1 other active

    1 trial

  18. LS11

    United Therapeutics Europe Ltd

    Neurofibroma

    phase 1 small molecule terminated

    1 trial

  19. LT-02-19

    Laboratorios Tillomed Spain S.L.U

    Chronic spontaneous urticaria, Allergic asthma, Chronic rhinosinusitis with nasal polyps

    phase 1 other active

    1 trial

  20. LTI-03

    Shanghai Reinovax Biologics Co.,LTD

    Idiopathic Pulmonary Fibrosis

    phase 1 small molecule completed

    1 trial

  21. LUCAR-20S CAR-T cells

    Nanjing Legend Biotech Co.

    Diffuse Large B Cell Lymphoma

    phase 1 small molecule terminated

    1 trial

  22. LUCAR-20SP cells

    Nanjing Legend Biotech Co.

    Relapsed B-cell Non-Hodgkin Lymphoma

    phase 1 mab active

    1 trial

  23. LUCAR-B68 cells product

    Nanjing Legend Biotech Co.

    Relapsed/Refractory Multiple Myeloma

    phase 1 mab active

    1 trial

  24. LUCAR-DKS1 NK cells

    Nanjing Legend Biotech Co.

    Relapsed/Refractory Autoimmune Diseases

    phase 1 mab active

    1 trial

  25. LUCAR-E9D or LUCAR-E9K cells product

    The First People's Hospital of Lianyungang

    B-cell Non-Hodgkin Lymphoma Recurrent B-cell Non-Hodgkin Lymphoma Refractory

    phase 1 mab active

    1 trial

  26. LUCAR-G39D cells product

    Nanjing Legend Biotech Co.

    B-Cell Non-Hodgkin Lymphoma-Recurrent

    phase 1 mab active

    1 trial

  27. LUCAR-G39P cells product

    The First People's Hospital of Lianyungang

    Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

    phase 1 mab terminated

    1 trial

  28. LUCAR-G79 T cells

    Nanjing Legend Biotech Co.

    Relapsed/Refractory Autoimmune Diseases

    phase 1 mab active

    1 trial

  29. LUCAR-G79D T cells

    Nanjing Legend Biotech Co.

    Systemic Lupus Erythematosus (SLE)

    phase 1 mab active

    1 trial

  30. LVIVO-TaVec200 product

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 1 mab active

    1 trial

  31. LVIVO-TaVec400 product

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multiple Myeloma (MM)

    phase 1 mab active

    1 trial

  32. LVIVO-TaVec400 product

    Nanjing Legend Biotech Co.

    Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE)

    phase 1 mab active

    1 trial

  33. LX1001

    Lexeo Therapeutics

    Alzheimer Disease

    phase 1 mab active

    1 trial

  34. LX3305

    LEXICON PHARMACEUTICALS, INC.

    Rheumatoid Arthritis

    phase 1 small molecule completed

    1 trial

  35. LX4211

    LEXICON PHARMACEUTICALS, INC.

    Healthy

    phase 1 small molecule completed

    1 trial

  36. LX4211

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 1 small molecule completed

    2 trials

  37. LX4211 400 mg

    LEXICON PHARMACEUTICALS, INC.

    Healthy

    phase 1 small molecule completed

    1 trial

  38. LX4211 400 mg

    LEXICON PHARMACEUTICALS, INC.

    Healthy Subjects

    phase 1 small molecule completed

    1 trial

  39. LX4211 800 mg

    LEXICON PHARMACEUTICALS, INC.

    Healthy

    phase 1 small molecule completed

    1 trial

  40. LY007

    The First People's Hospital of Lianyungang

    B-NHL

    phase 1 small molecule active

    1 trial

  41. LY03010/CT-EUR-102

    Lacuna Pharma Pty Ltd

    Schizophrenia

    phase 1 other active

    1 trial

  42. LY2456302

    Krystal Biotech Netherlands B.V.

    Anxiety Disorders

    phase 1 small molecule terminated

    1 trial

  43. LY3039478

    Eli Lilly and Company

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial

  44. LY3053102

    Eli Lilly and Company

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  45. LY3209590 (SC)

    Eli Lilly and Company

    Healthy

    phase 1 small molecule completed

    1 trial

  46. LY3471851

    Nektar Therapeutics UK Limited

    Dermatitis, Atopic

    phase 1 small molecule completed

    1 trial

  47. LY3471851

    Nektar Therapeutics UK Limited

    Healthy

    phase 1 small molecule completed

    4 trials

  48. LY3484356

    Eli Lilly and Company

    Breast Neoplasms

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many Phase I pipeline programs are in the directory?

4,713 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.